At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way.
Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology."a resource that will likely serve as a standard for years to come"
- Dr Jonathan Seltzer
Therapeutic Innovation & Regulatory Science, 2017;51(2):180
"I have no hesitation in recommending this book as a valuable reference source"
- Dr Rashmi Shah
Journal for Clinical Studies, 2017;9(1):62-63
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
J. Rick Turner, BSc (Hons), PGCE, PhD, DSc, is an experimental research scientist, clinical trialist, author, editor, and educator. He spent the first part of his professional career in the field of Cardiovascular Behavioral Medicine, detailing the individual differences apparent in cardiovascular responses to behavioral and psychological stressors, including genetic influences upon them. He received two international awards for his research, and is Co-Editor of the 2013 Springer volume Encyclopedia of Behavioral Medicine, the definitive work in this area.
Dr Turner is currently Chief Scientific Advisor, Cardiac Safety Services, and Senior Scientific Director, Clinical Communications, Quintiles. He is also member of Quintiles' Cardiovascular and Diabetes Centers of Excellence. He is the author and co-author of over 120 publications in peer-reviewed journals, and the author, co-author, and editor of 15 books. Additionally, he holds the positions of Adjunct Professor of Pharmacy Practice, Campbell University College of Pharmacy & Health Sciences, and President and Chief Scientific Officer, Turner Medical Communications.
Dilip R. Karnad, MD, FACP, FRCP (Glasg), is an internist and an expert in cardiac safety with extensive clinical, research and teaching experience. He is currently Head of the Research Team, Cardiac Safety Services, Quintiles. He has a particular interest in statistical approaches to cardiac safety assessments, and has published over 20 papers in this field. He is a Fellow of the American College of Physicians and a Fellow of the Royal College of Physicians (of Glasgow), and also a practicing internist and critical care physician affiliated to Jupiter Hospital, Thane.
Snehal Kothari, MD, DM, FACC, FESC is a cardiologist and an expert in cardiac safety with extensive clinical, research and teaching experience. He is currently Chief Medical & Scientific Officer of theCore ECG Laboratory, Cardiac Safety Services, and Global Head of the Cardiac Safety Centre of Excellence, Quintiles. He is also a practicing Interventional Cardiologist affiliated to Lilavati Hospital & Research Centre, Mumbai. He is the recipient of over 30 awards and honors, and is a Fellow of the American College of Cardiology, the European Society of Cardiology, and the Asian Pacific Society of Cardiology. He has over 80 peer-reviewed publications and published abstracts.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Etat : new. Questo è un articolo print on demand. N° de réf. du vendeur c00f350b467c19ceb3649d5fe1e54caa
Quantité disponible : Plus de 20 disponibles
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitroProarrhythmia Assay initiative is well under way.Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology.'a resource that will likely serve as a standard for years to come'- Dr Jonathan SeltzerTherapeutic Innovation & Regulatory Science, 2017;51(2):180'I have no hesitation in recommending this book as a valuable reference source'- Dr Rashmi ShahJournal for Clinical Studies, 2017;9(1):62-63 368 pp. Englisch. N° de réf. du vendeur 9783319403458
Quantité disponible : 2 disponible(s)
Vendeur : moluna, Greven, Allemagne
Gebunden. Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Cutting-edge descriptions and explanations of state-of-the-art cardiovascular safety assessments enable readers to get up to speed quickly.  No other book provides such a comprehensive overview of one of the most important topics in drug development. N° de réf. du vendeur 121215857
Quantité disponible : Plus de 20 disponibles
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitroProarrhythmia Assay initiative is well under way.Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology.'a resource that will likely serve as a standard for years to come'- Dr Jonathan SeltzerTherapeutic Innovation & Regulatory Science, 2017;51(2):180'I have no hesitation in recommending this book as a valuable reference source'- Dr Rashmi ShahJournal for Clinical Studies, 2017;9(1):62-63. N° de réf. du vendeur 9783319403458
Quantité disponible : 1 disponible(s)
Vendeur : Books Puddle, Woodside, NY, Etats-Unis
Etat : New. pp. 357. N° de réf. du vendeur 26374878971
Quantité disponible : 4 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Buch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way.Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology.'a resource that will likely serve as a standard for years to come' Dr Jonathan SeltzerTherapeutic Innovation & Regulatory Science, 2017;51(2):180'I have no hesitation in recommending this book as a valuable reference source' Dr Rashmi ShahJournal for Clinical Studies, 2017;9(1):62-63Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 368 pp. Englisch. N° de réf. du vendeur 9783319403458
Quantité disponible : 1 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. Print on Demand pp. 357. N° de réf. du vendeur 372215076
Quantité disponible : 4 disponible(s)
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Etat : New. PRINT ON DEMAND pp. 357. N° de réf. du vendeur 18374878961
Quantité disponible : 4 disponible(s)
Vendeur : Buchpark, Trebbin, Allemagne
Etat : Sehr gut. Zustand: Sehr gut | Seiten: 368 | Sprache: Englisch | Produktart: Bücher | At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way.Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology.¿a resource that will likely serve as a standard for years to come¿ - Dr Jonathan SeltzerTherapeutic Innovation & Regulatory Science, 2017;51(2):180¿I have no hesitation in recommending this book as a valuable reference source¿ - Dr Rashmi ShahJournal for Clinical Studies, 2017;9(1):62-63. N° de réf. du vendeur 26784557/12
Quantité disponible : 1 disponible(s)
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
Hardcover. Etat : Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book. N° de réf. du vendeur ERICA80033194034516
Quantité disponible : 1 disponible(s)